FDA Accepts Kabi’s Actemra Biosimilar – Will It Be First?
German Firm Plans Both US And EU Launches In 2023
Executive Summary
Fresenius Kabi has been tipped to strike first in the race to launch a biosimilar to Actemra – a market where competition “is likely to be thin for some time.”